STAT+: A rival goes after Ocular Therapeutix on eve of pivotal readout on eye treatment
Stat News • 2/5/2026
Summary
Ocular Therapeutix and Eyepoint Pharmaceuticals are developing competing eye treatments. The competition between the two companies is intensifying as Ocular Therapeutix approaches a pivotal readout on its eye treatment.
Advertisement
Lindy Score Breakdown (V4.2)
57d
Age
1
Sources
from cluster
1382
Hours Since Seen
Final Score0/100
CategoryAntiLindy
StatusArchived
Recency Multiplier0% (0.5^1382/48)
Hero EligibleNo
Score is 0 because recency decay (0.5^1382/48 = 0.000000) reduced it below 0.5
Score BreakdownRisk 50
Source Reputation: Low-trust source (4/20 pts)
Consensus: Single source - no independent confirmation yet
Age: 57 days - proven survivor
Stories gain Lindy status through source reputation, network consensus, and time survival.
Breaking Similar stories
STAT reporter goes up against radiologists to spot deepfake X-rays
Stat News • 2 days ago
STAT+: Lilly’s obesity pill enters the oral GLP-1 game, Novo responds
Stat News • 1 day ago
Opinion: STAT+: Cardiology’s finally prioritizing prevention — but what will it look like?
Stat News • 2 days ago
STAT+: ‘Takeover Tuesday’ saves biotech’s quarter
Stat News • 2 days ago
STAT+: Makary marks one year at FDA with focus on achievements in speech to staff
Stat News • 2 days ago
STAT+: Large AI scribe study finds modest time savings, inconsistent use
Stat News • 2 days ago
STAT+: Proposed ‘preclinical obesity’ diagnosis ignites global debate among experts
Stat News • 1 day ago
STAT+: Pharmalittle: We’re reading about FDA view on peptide compounding, Iran war hurting trial recruitment, and more
Stat News • 2 days ago
STAT+: Insilico Medicine CEO on how best to use AI in drug development
Stat News • 2 days ago
STAT+: Novo’s subscription model raises questions about pharma-telehealth tie-ups
Stat News • 2 days ago
Anti-Lindy Similar stories
STAT+: Pharmalittle: We’re reading about a Merck acquisition, the rise of former Loxo execs at Lilly, and more
Stat News • 1 week ago
STAT+: Pharmalittle: We’re reading about an FDA OK for a rare disease drug, a grilling of the PTO chief, and more
Stat News • 1 week ago
STAT+: Pharmalittle: We’re reading about Trump pushing drug pricing policy, Chinese biotech licensing, and more
Stat News • 4 days ago
STAT+: FDA approves Denali Therapeutics drug for Hunter syndrome
Stat News • 1 week ago